Abstract 305P
Background
The prognosis in patients with breast cancer with isolated locoregional recurrence (ILRR) without simultaneous distant metastases after immediate breast reconstruction (IBR) remains unknown. We aimed to investigate the prognosis in this patient population.
Methods
This multi-institutional retrospective observational study evaluated 3,295 patients with primary breast cancer who underwent IBR at 12 Japanese medical facilities between January 1, 2008 and December 31, 2016. The outcome measures were the prognostic factors for ILRR after IBR, 5-year distant metastasis-free survival (DMFS), and 5-year overall survival (OS).
Results
Mastectomy or skin-sparing mastectomy was performed in 3,295 patients. ILRR occurred in 70 patients, and the median observation period from ILRR diagnosis was 39.3 months. Of the 70 patients, 9 (12.9%) had axillary lymph node recurrence (ALNR) at the time of ILRR diagnosis. The 5-year DMFS after ILRR was 92.4%. Patients with ILRR who had ALNR had a significantly worse DMFS than that had by those without ALNR (P = 0.005).The 5-year OS after ILRR was 91.2%. Patients with ILRR who had ALNR had a significantly worse OS than that had by those without ALNR (P = 0.005).The relationship between DMFS and clinicopathological factors was analyzed using the Cox proportional hazards model. Univariate analysis revealed significant associations of pN at primary surgery (P = 0.041) and ALNR at ILRR (HR: 9.960, 95% CI: 1.400–70.862, P = 0.022) with DMFS. However, ALNR was the only independent prognostic factor for DMFS in the multivariate analysis (P = 0.041). Univariate analysis revealed significant associations of post-mastectomy radiation therapy (PMRT) at primary surgery (P = 0.023) and ALNR at ILRR (P = 0.043) with OS. In multivariate analysis, both PMRT (P = 0.010) and ALNR (P = 0.028) were independent prognostic factors for OS.
Conclusions
Although patients with breast cancer who have ILRR after IBR have a favorable prognosis overall, ALNR at the diagnosis of ILRR may be a poor prognostic factor. Our results may contribute to developing strategies to predict prognosis in patients with breast cancer who develop ILRR after IBR.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
259P - Relationship between initial tumor burden and the probability of pathological complete response within molecular subtypes of early breast cancer treated with neoadjuvant chemotherapy
Presenter: Nicolas Roussot
Session: Poster session 14
260P - Impact of HER2-low status on clinicopathological characteristics and pathological complete response in luminal and triple-negative early breast cancer
Presenter: Katarzyna Pogoda
Session: Poster session 14
261P - Subtyping of residual disease (RD) following neoadjuvant chemotherapy (NACT) for triple negative breast cancer (TNBC): Evolution and prognostic impact
Presenter: Isabel Echavarria Diaz-Guardamino
Session: Poster session 14
262P - Predictive clinico-biological factors of toxicity associated to neo-adjuvant chemo- immunotherapy in early-stage triple-negative breast cancer
Presenter: Elsa Volant
Session: Poster session 14
263P - Association between clinicopathological characteristics and pathological complete response in patients with triple negative breast cancer treated by neoadjuvant chemo-immunotherapy
Presenter: Clara Helal
Session: Poster session 14
264P - Neuropsychological and morphological effects of simultaneous exercise during neo-/adjuvant chemotherapy in breast cancer patients: The Exercise Cancer and Cognition (ECCO) study
Presenter: David Kiesl
Session: Poster session 14
265P - Association of clinical benefit of adjuvant capecitabine and RCB class in triple negative breast cancer (TNBC) patients with residual disease following neoadjuvant chemotherapy
Presenter: Shinyoung Lee
Session: Poster session 14
266P - Association of RAD51 and efficacy outcomes in patients with HER2-negative breast cancer (BC) and homologous recombination deficiency (HRD): Post-hoc analysis of the GeparOla trial
Presenter: Guillermo Villacampa
Session: Poster session 14
267P - The tumour microenvironment influences long-term tamoxifen treatment response in breast cancer patients
Presenter: Paula Camargo Romera
Session: Poster session 14
268P - Impact of B cell and plasma cell infiltration on survival in early-stage breast cancer (BC) without recurrence
Presenter: Laura Angelats
Session: Poster session 14